OTCMKTS:CYDY CytoDyn (CYDY) Stock Price, News & Analysis → Musk’s new company could top a trillion? (From Paradigm Press) (Ad) Free CYDY Stock Alerts $0.13 0.00 (0.00%) (As of 06/14/2024 ET) Add Compare Share Share Today's Range$0.13▼$0.1450-Day Range$0.13▼$0.3052-Week Range$0.13▼$0.42Volume3.71 million shsAverage Volume4.63 million shsMarket Capitalization$133.27 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort Interest Get CytoDyn alerts: Email Address Ad Paradigm PressMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just released the details on what he’s calling Elon’s Project X-9840. Click here to see the details because there’s not much time to prepare. About CytoDyn Stock (OTCMKTS:CYDY)CytoDyn Inc., a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer. Its leronlimab is currently under phase 2 development for the treatment of NASH, HIV- NASH, and solid tumors, as well as under pre-clinical development for the treatment of HIV-PrEP and HIV-Cure. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.Read More CYDY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CYDY Stock News HeadlinesMay 28, 2024 | globenewswire.comCytoDyn to Host Webcast to Provide Company UpdateMay 16, 2024 | globenewswire.comMay 2024 Letter to ShareholdersFebruary 29, 2024 | markets.businessinsider.comCytoDyn Says FDA Lifts Hold On LeronlimabFebruary 29, 2024 | msn.comFDA lifts clinical hold on CytoDyn drug, stock rallies 22%February 29, 2024 | globenewswire.comCytoDyn Announces FDA Has Lifted Clinical HoldFebruary 10, 2024 | morningstar.comCytoDyn Inc CYDYFebruary 1, 2024 | markets.businessinsider.comCytoDyn Submits Revised HIV Clinical Trial Protocol To FDA, Starts Glioblastoma Pre-Clinical StudyFebruary 1, 2024 | finance.yahoo.comCytoDyn Announces Submission of Clinical Protocol to FDA and Initiation of Pre-Clinical Study in GlioblastomaFebruary 1, 2024 | tmcnet.comCytoDyn Announces Submission of Clinical Protocol to FDA and Initiation of Pre-Clinical Study in GlioblastomaJanuary 31, 2024 | bizjournals.comInvestors file another lawsuit against CytoDynJanuary 30, 2024 | msn.comCytoDyn Releases Regulatory FD Disclosure InformationJanuary 30, 2024 | msn.comCytoDyn Announces Executive Leadership Changes and AppointmentsJanuary 29, 2024 | bizjournals.comVancouver biotech appoints new CEO, as former top executive awaits fraud trialJanuary 29, 2024 | finanznachrichten.deCytoDyn Inc.: CytoDyn Appoints Jacob Lalezari M.D. as CEO, Mitchell Cohen as Interim CFOJanuary 29, 2024 | msn.comCytoDyn appoints Jacob Lalezari as CEO, Mitchell Cohen as interim CFOJanuary 29, 2024 | finance.yahoo.comCytoDyn Appoints Jacob Lalezari M.D. as CEO, Mitchell Cohen as Interim CFODecember 7, 2023 | finance.yahoo.comCytoDyn Announces Webcast to Provide Company UpdateNovember 22, 2023 | msn.comCytoDyn appoints Lalezari as its interim CEONovember 21, 2023 | finanznachrichten.deCytoDyn Inc.: CytoDyn Appoints Jacob Lalezari M.D. as Interim CEONovember 21, 2023 | finance.yahoo.comCytoDyn Appoints Jacob Lalezari M.D. as Interim CEOSeptember 21, 2023 | bizjournals.comFormer biotech execs in 'brazen fraud' case want indictments dismissedAugust 2, 2023 | fool.comCytoDyn (OTC: CYDY)July 24, 2023 | bizjournals.comCytoDyn leader on taking HIV treatment back to FDA, is upbeat about Amarex litigationJuly 13, 2023 | benzinga.comDevelopments in OTC Stocks Under a Quarter (CSTF, CYDY, IMHC, BRLL)July 12, 2023 | bizjournals.comCytoDyn hits up former business partner for $100M in damagesSee More Headlines Receive CYDY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CytoDyn and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/15/2024Today6/15/2024Fiscal Year End5/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:CYDY Previous SymbolNASDAQ:CYDY CUSIP23283M101 CIK1175680 Webwww.cytodyn.com Phone(360) 980-8524FaxN/AEmployees12Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.05) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-79,820,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-478.47% Debt Debt-to-Equity RatioN/A Current Ratio0.08 Quick Ratio0.08 Sales & Book Value Annual Sales$270,000.00 Price / Sales493.60 Cash FlowN/A Price / Cash FlowN/A Book Value($0.12) per share Price / Book-1.12Miscellaneous Outstanding Shares993,830,000Free Float986,770,000Market Cap$133.27 million OptionableNot Optionable Beta0.21 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesDr. Cyrus Arman M.B.A. (Age 42)Ph.D., Senior Vice President of Business Operations Comp: $451.17kDr. Jacob P. Lalezari M.D. (Age 64)CEO & Member of Scientific Advisory Board Mr. Mitchell Cohen (Age 67)Interim Chief Financial Officer Mr. Tyler Blok (Age 36)Executive Vice President of Legal Affairs & Secretary Dr. Scott Hansen Ph.D.Head of Research & Basic ScienceMr. Joseph MeidlingExecutive Director of Clinical OperationsMs. Cristina De LeonInvestorsMore ExecutivesKey CompetitorsEsperion TherapeuticsNASDAQ:ESPRHeron TherapeuticsNASDAQ:HRTXCartesian TherapeuticsNASDAQ:RNACNorthwest BiotherapeuticsOTCMKTS:NWBOORIC PharmaceuticalsNASDAQ:ORICView All Competitors CYDY Stock Analysis - Frequently Asked Questions How have CYDY shares performed in 2024? CytoDyn's stock was trading at $0.1950 on January 1st, 2024. Since then, CYDY stock has decreased by 31.2% and is now trading at $0.1341. View the best growth stocks for 2024 here. Are investors shorting CytoDyn? CytoDyn saw a increase in short interest in the month of May. As of May 31st, there was short interest totaling 8,060,300 shares, an increase of 72.7% from the May 15th total of 4,666,400 shares. Based on an average daily trading volume, of 10,249,200 shares, the days-to-cover ratio is currently 0.8 days. View CytoDyn's Short Interest. How were CytoDyn's earnings last quarter? CytoDyn Inc. (OTCMKTS:CYDY) issued its quarterly earnings data on Monday, April, 15th. The biotechnology company reported ($0.01) earnings per share for the quarter. What other stocks do shareholders of CytoDyn own? Based on aggregate information from My MarketBeat watchlists, some companies that other CytoDyn investors own include Inovio Pharmaceuticals (INO), Novavax (NVAX), NVIDIA (NVDA), Johnson & Johnson (JNJ), Gilead Sciences (GILD), Vaxart (VXRT), Nokia Oyj (NOK), Pfizer (PFE), Sorrento Therapeutics (SRNE) and Moderna (MRNA). How do I buy shares of CytoDyn? Shares of CYDY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:CYDY) was last updated on 6/15/2024 by MarketBeat.com Staff From Our PartnersTiny, One-Half Inch Pellet the Key to INFINITE Energy?It’s a tiny, $1 billion company that holds the key to this power. And yet, it’s the largest company of its ...Eagle Publishing | SponsoredMoonshot Coins for the Current Crypto RunAre you monitoring 13,217 cryptocurrencies everyday? If not, you could miss the ONE that can make you wealt...Crypto 101 Media | SponsoredGold Set to EXPLODE!The perfect storm is brewing to drive gold's price through the roof! And our weakening dollars are causing ...Gold Safe Exchange | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredHow Biden has already won 2024Obama’s Forever Term [Exposed] or Obama Biden has already won 2024 Exposed: the shocking election plot that...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CytoDyn Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CytoDyn With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.